Better Therapeutics (NASDAQ:BTTX) is a stock on the move. Over the past month, the microcap stock has posted gains of 80%, according to PennyStocks.com.
At last check, the stock had reached $2.28 in early trading on May 26th. So, is this impressive run going to continue?
What’s Really Behind Better Therapeutics Rise
Many companies, including penny stocks, in the health market are posting serious gains in today’s marketplace. A quick look at Better Therapeutics’ recent company news indicates several positive developments that could help power it even higher. For instance:
- On May 13, the company reported positive endpoint results for the trial of its Type II Diabetes treatment – BT-001.
- Also, on May 13, the company reported good First Quarter financials, including cash and cash equivalents of $31.7 million and a $5 million borrowing capacity on its secured loan agreement with Hercules Capital, Inc.
This appears to be a well-funded company that is making significant progress toward achieving key milestones. Examples include:
- BT-001 displayed an excellent safety profile and produced significant improvement in A1c compared to the control in that recently finished 90-day clinical trial.
- Better Therapeutics (NASDAQ:BTTX) joined a real-world evidence study at the Durham Veterans Administration (VA) Medical Center to produce evidence that supports payer coverage and reimbursement.
- The company launched a clinical trial to determine if its nCBT treatment can reduce liver fat and improve liver disease biomarkers for Nonalcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic SteatoHepatitis (NASH). No FDA-approved therapeutics for NASH/NAFLD are currently available, the company says.
Progress Comes as Health Concerns Grow
All of this progress by Better Therapeutics (NASDAQ:BTTX) appears to be coming at an ideal time as Science Daily reports that over 95% of the world’s population now has health concerns. Cardiovascular-related problems have always been one of the biggest health issues many people face.
While such things as COVID-19 and Monkeypox are getting the headlines, cardiovascular problems are still the number one killer of adults.
The CDC reports that “heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups in the United States.” It also says “one person dies every 36 seconds in the United States from cardiovascular disease.”
Cardiometabolic disorders are a leading precursor of serious cardiovascular problems, and Better Therapeutics is a penny stock that is carving out a first-mover advantage thanks to its breakthrough treatment model that features behavioral therapy delivered as prescription digital therapeutics.
Featured Image: Megapixl @Darren4155
